| Identification | Back Directory | [Name]
N,N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine | [CAS]
72238-02-9 | [Synonyms]
BD-84
Retelliptine
NSC-D-626717-W
SR-95325B (diHCl)
SR-95325A (dimaleate)
1-(3-Diethylaminopropylamino)-5,11-dimethyl-9-methoxy-6H-pyrido[4,3-b]carbazole
N-[3-(Diethylamino)propyl]-5,11-dimethyl-9-methoxy-6H-pyrido[4,3-b]carbazole-1-amine
N,N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine
N,N-Diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-1,3-propanediamine
N,N-Diethyl-N'-(5,11-dimethyl-9-methoxy-6H-pyrido[4,3-b]carbazole-1-yl)-1,3-propanediamine
1,3-Propanediamine,N1,N1-diethyl-N3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)- | [EINECS(EC#)]
276-512-5 | [Molecular Formula]
C25H32N4O | [MDL Number]
MFCD00868791 | [MOL File]
72238-02-9.mol | [Molecular Weight]
404.55 |
| Hazard Information | Back Directory | [Uses]
Retelliptine (BD84), a derivative of ellipticine, is an inhibitor of Topoisomerase II with anticancer activity. Retelliptine can bind to DNA and inhibit Topoisomerase II during DNA replication[1][2]. | [References]
[1] Kattan J, et al. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule[J]. American journal of clinical oncology, 1994, 17(3): 242-245. DOI:10.1097/00000421-199406000-00013
[2] Maulard C, et al. Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes[J]. Biochemical pharmacology, 1990, 40(4): 895-898. DOI:10.1016/0006-2952(90)90333-g |
|
|